Serina surges 37% after FDA clears Parkinson’s drug for trials
Serina Therapeutics stock jumped 37% in after-hours trade after the FDA backed advancing its Parkinson's drug SER-252 into a registrational program. The decision followed a Type B meeting, clearing the way for an IND filing in late 2025 and global patient enrollment next year. Retail traders on Stocktwits turned 'extremely bullish', fueling speculation of more upside.